Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy AbCellera Biologics stock | $26.83
Learn how to easily invest in AbCellera Biologics stock.
AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.
How to buy shares in AbCellera Biologics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ABCL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
AbCellera Biologics stock price (NASDAQ: ABCL)Use our graph to track the performance of ABCL stocks over time.
AbCellera Biologics shares at a glance
|Latest market close||$26.83|
|52-week range||$15.80 - $71.91|
|50-day moving average||$21.18|
|200-day moving average||$32.04|
|Wall St. target price||$51.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.78|
Buy AbCellera Biologics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy AbCellera Biologics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AbCellera Biologics price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||21.95%|
|3 months (2021-04-30)||0.68%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Is AbCellera Biologics under- or over-valued?
Valuing AbCellera Biologics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbCellera Biologics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbCellera Biologics's P/E ratio
AbCellera Biologics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, AbCellera Biologics shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, AbCellera Biologics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
AbCellera Biologics's EBITDA
AbCellera Biologics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $325.7 million.
The EBITDA is a measure of a AbCellera Biologics's overall financial performance and is widely used to measure a its profitability.
To put AbCellera Biologics's EBITDA into context you can compare it against that of similar companies.
AbCellera Biologics financials
|Revenue TTM||$431.2 million|
|Operating margin TTM||73.77%|
|Gross profit TTM||$176.6 million|
|Return on assets TTM||30.98%|
|Return on equity TTM||49.25%|
|Market capitalisation||$4.5 billion|
TTM: trailing 12 months
Shorting AbCellera Biologics shares
There are currently 8.4 million AbCellera Biologics shares held short by investors – that's known as AbCellera Biologics's "short interest". This figure is 17.8% up from 7.1 million last month.
There are a few different ways that this level of interest in shorting AbCellera Biologics shares can be evaluated.
AbCellera Biologics's "short interest ratio" (SIR)
AbCellera Biologics's "short interest ratio" (SIR) is the quantity of AbCellera Biologics shares currently shorted divided by the average quantity of AbCellera Biologics shares traded daily (recently around 2.5 million). AbCellera Biologics's SIR currently stands at 3.36. In other words for every 100,000 AbCellera Biologics shares traded daily on the market, roughly 3360 shares are currently held short.
To gain some more context, you can compare AbCellera Biologics's short interest ratio against those of similar companies.
However AbCellera Biologics's short interest can also be evaluated against the total number of AbCellera Biologics shares, or, against the total number of tradable AbCellera Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AbCellera Biologics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 AbCellera Biologics shares in existence, roughly 30 shares are currently held short) or 0.0552% of the tradable shares (for every 100,000 tradable AbCellera Biologics shares, roughly 55 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AbCellera Biologics.
Find out more about how you can short AbCellera Biologics stock.
AbCellera Biologics share dividends
We're not expecting AbCellera Biologics to pay a dividend over the next 12 months.
AbCellera Biologics overview
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
Frequently asked questionsWhat percentage of AbCellera Biologics is owned by insiders or institutions?
Currently 32.456% of AbCellera Biologics shares are held by insiders and 41.84% by institutions. How many people work for AbCellera Biologics?
Latest data suggests 206 work at AbCellera Biologics. When does the fiscal year end for AbCellera Biologics?
AbCellera Biologics's fiscal year ends in December. Where is AbCellera Biologics based?
AbCellera Biologics's address is: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert